Insider Trading

Notable insider buying and selling activity across public companies.

Tracking and analysis of reported insider transactions, including executive and director buying or selling. Insider activity can offer insight into internal confidence, valuation perceptions, and potential inflection points.

Articles

10,710 total articles

Twilio CFO Executes $1.01M in Sell-to-Cover Stock Transactions

Twilio CFO Executes $1.01M in Sell-to-Cover Stock Transactions

Twilio Inc. Chief Financial Officer Aidan Viggiano completed $1,010,653 in Class A share sales on March 31, 2026, via a series of sell-to-cover transactions mandated under the company’s equity incentive plan. The trades, disclosed on a Form 4 filing, reduced withholding obligations but do not reflect discretionary selling. Twilio’s stock trades abo…

Vita Coco CCO Executes $97,340 Share Sale Under Rule 10b5-1 Plan

Vita Coco CCO Executes $97,340 Share Sale Under Rule 10b5-1 Plan

Charles van Es, Chief Commercial Officer at The Vita Coco Company, Inc. (NASDAQ: COCO), sold 2,000 shares on April 1, 2026, for $97,340 under a Rule 10b5-1 plan. The transaction follows a 61% 12-month stock run and comes amid analyst price-target increases and a board appointment for retail executive Shelley Broader. Analysis tools cited in filings…

First Guaranty Bancshares Director Increases Stake with $250,007 Purchase; Bank Agrees Loan Amendments

First Guaranty Bancshares Director Increases Stake with $250,007 Purchase; Bank Agrees Loan Amendments

Marshall T. Reynolds, a director of First Guaranty Bancshares, Inc. (NASDAQ: FGBI), purchased 32,176 shares on March 31, 2026, for $7.77 per share, a $250,007 investment. The stock has since traded at $9.20, a 64% year-to-date rise. Reynolds' direct and indirect holdings are detailed, and the bank disclosed amendments to two loan agreements with Sm…

Interactive Brokers Director Adds to Position With $1,709 Purchase

Interactive Brokers Director Adds to Position With $1,709 Purchase

Lori A. Conkling, a director at Interactive Brokers Group, purchased 25 shares of Class A common stock on April 1, 2026, for $68.38 each, a total outlay of $1,709. The transaction leaves Conkling with 2,434 shares directly held. The move coincides with robust fourth-quarter 2025 financials, product expansions in crypto derivatives and Canadian reti…

Williams Companies General Counsel Sells $143,500 in Stock; Firm Sees Multiple Analyst Target Increases

Williams Companies General Counsel Sells $143,500 in Stock; Firm Sees Multiple Analyst Target Increases

Terrance Lane Wilson, senior vice president and general counsel of Williams Companies, sold 2,000 shares of the company's common stock on April 1, 2026, for $71.75 per share, realizing $143,500. The transaction was carried out under a 10b5-1 trading plan and leaves Wilson with 289,159 shares directly and 100 shares indirectly through a trust. Separ…

Lynx1 Increases Stake in Korro Bio with Small Open-Market Purchase

Lynx1 Increases Stake in Korro Bio with Small Open-Market Purchase

Lynx1 Capital Management L.P., a roughly 10% holder of Korro Bio, Inc. (NASDAQ: KRRO), purchased 520 shares of common stock on March 31, 2026, at $10.60 per share for a total of $5,512. The company’s shares have since traded up to $13.85, a roughly 30% increase from the purchase price. Korro Bio has also announced an $85 million private equity fina…

Gold.com Insider Sells $800,000 in Stock as Company Completes Sunshine Minting Buy and Secures $150M Placement

Gold.com Insider Sells $800,000 in Stock as Company Completes Sunshine Minting Buy and Secures $150M Placement

William A. Richardson disposed of 20,000 shares of Gold.com, Inc. (NASDAQ:GOLD) on March 31, 2026, for $40.00 per share, realizing $800,000. The transaction occurred while the shares traded near $40.91, following a roughly 70% return over the prior 12 months. Gold.com finalized acquisition of the remaining 55.1% of Sunshine Minting, Inc., and annou…

Vir Biotechnology Director Sato Disposes $199,616 in Shares

Vir Biotechnology Director Sato Disposes $199,616 in Shares

Vicki L. Sato, a director at Vir Biotechnology, sold 22,000 shares on April 1, 2026 under a Rule 10b5-1 plan, generating $199,616 in proceeds. The transaction comes amid recent equity offerings and analyst price-target increases tied to a collaboration with Astellas Pharma; Vir's shares have returned 59% over the past six months.